BriaCell Therapeutics Corp. (BCTX) earnings date, results and what the price requires
Nasdaq · SEC CIK 0001610820 · SEC filings checked Oct 18, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Apr 30, 2026 | Jun 9, 2026 | — | $-7.2M | $-0.99 | Filing |
| Jan 31, 2026 | Mar 10, 2026 | — | $-7.2M | $-2.58 | Filing |
| Oct 31, 2025 | Dec 11, 2025 | — | $-8.2M | $-4.35 | Filing |
| Jul 31, 2025 | Oct 16, 2025 | — | $-8.1M | $10.21 | Filing |
| Apr 30, 2025 | Jun 16, 2025 | — | $-6.1M | $-16.42 | Filing |
| Jan 31, 2025 | Mar 12, 2025 | — | $-6.3M | $-23.31 | Filing |
| Oct 31, 2024 | Dec 16, 2024 | — | $-5.8M | $-32.67 | Filing |
| Jul 31, 2024 | Oct 29, 2024 | — | $-1.2M | $-34.15 | Filing |
What would BriaCell Therapeutics Corp. have to report for its valuation to change?
At $3.40, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about -33.8% a year, to $0.29. On that path the next quarter needs diluted EPS near $6.76, against $10.21 in the quarter ended Jul 31, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | -33.8% | -33.8% |
| EPS needed in final year | $0.29 | $0.29 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. BCTX goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.